Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma

Leukemia. 2021 Jan;35(1):255-258. doi: 10.1038/s41375-020-0834-9. Epub 2020 Apr 21.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Immunological / administration & dosage
  • Antineoplastic Agents, Immunological / adverse effects
  • Antineoplastic Agents, Immunological / therapeutic use*
  • B-Cell Maturation Antigen / antagonists & inhibitors*
  • Drug Resistance, Neoplasm
  • Humans
  • Immunoconjugates / administration & dosage
  • Immunoconjugates / adverse effects
  • Immunoconjugates / therapeutic use*
  • Multiple Myeloma / diagnosis
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / etiology
  • Multiple Myeloma / mortality
  • Recurrence
  • Retreatment
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Immunological
  • B-Cell Maturation Antigen
  • Immunoconjugates
  • TNFRSF17 protein, human